Castle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024

Rhea-AI Summary

Castle Biosciences, Inc. (Nasdaq: CSTL) will release its financial results for the fourth quarter and year ended Dec. 31, 2023, after the close of market on Wednesday, Feb. 28, 2024. The company will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Access details for the webcast and phone conference call are provided in the press release.

FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2023, after the close of market on Wednesday, Feb. 28, 2024.

Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day.

Conference Call and Webcast Details

A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/610272350, or via the webcast link on the Investor Relations page of the Company’s website: https://ir.castlebiosciences.com/overview/default.aspx. Please access the webcast at least 10 minutes before the conference call start time. A replay of the webcast will be available following the conclusion of the conference call.

To access the live conference call via phone, please dial 1 833 470 1428 from the United States, at least 10 minutes prior to the start of the call, using the access code 036526. International dial-in numbers are available here: https://www.netroadshow.com/events/global-numbers?confId=60356; please use the same access code above to join the call.

There will be a brief Question and Answer session following management commentary.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240207643265/en/

Investor Contact:

Camilla Zuckero

czuckero@castlebiosciences.com

Media Contact:

Allison Marshall

amarshall@castlebiosciences.com

Source: Castle Biosciences Inc.

FAQ

When will Castle Biosciences release its financial results for the fourth quarter and year ended Dec. 31, 2023?

Castle Biosciences will release its financial results on Wednesday, Feb. 28, 2024, after the close of market.

What is the ticker symbol for Castle Biosciences?

The ticker symbol for Castle Biosciences is CSTL.

How can I access the webcast of the conference call?

The live webcast of the conference call can be accessed through the webcast link on the Investor Relations page of the Company’s website or via the provided webcast link.

What time will the conference call to discuss financial results take place?

The conference call to discuss financial results will take place at 4:30 p.m. Eastern time on Wednesday, Feb. 28, 2024.

How can I access the live conference call via phone?

To access the live conference call via phone, please dial 1 833 470 1428 from the United States, at least 10 minutes prior to the start of the call, using the access code 036526.